職位描述
Talent@Boehringer Ingelheim
About Human Pharmaceutical Business
With global presence, Boehringer Ingelheim has industry-leading expertise in medicine research and development. We are constantly developing the next generation of medical breakthroughs and successfully delivering innovations to meet the medical needs of the patients we serve in the following key areas of interest: cardiovascular, respiratory, metabolic diseases, immunology, oncology and central nervous system. In the future, we will accelerate the launch of more than 10 innovative medicines to meet the demand of Chinese patients.
Job Responsibilities
-Lead and drive local project team to ensure deliverables in China-integration into global pipeline development for the T.C.M.
-Leading generation/updating of responsible new compounds /indications' China Clinical Development Plan (CDP); also provide clinical inputs to all clinical documents, including but not limited to protocols, study reports, etc.; provide clinical support to interacting with health authorities including CTA/NDA submissions, pre-IND/NDA meetings, panel meetings, etc.
-For China joining global trials, provide local medical support during trial execution, drive the China sub-group CTR generation; for China alone registration trials, provide full medical support to draft synopsis/protocol, trial execution and CTR generation etc.
-Build up and maintain close working connections with key stakeholders from internal, including both cooperate and local related cross functions from R&D and commercial; and external HA-reviewers/leading-investigators, etc.
Qualifications
-At least 7 years or more clinical medicine training background, M.D., Ph.D. will be plus
-Required capabilities (skills, experience, competencies):Has at least 2-5 years related clinical practice, and/or Medical-Affairs/Clinical-Development experience, more experience is needed for a Senior physician.
- 中國是BI全球焦點國家及全球新藥首發地 （"China In" Project）
- ***跨國外企全面參加各治療領域全球早期臨床研究（“China Key" Project）
- 75%研發管線同類首創 （first in class）
To understand more detail information about “China In” project and “China Key” project, please refer to: http://www.dxy.cn/c/wxpub/669614
